Ineffectiveness of rosiglitazone therapy in Nelson's syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 5, 2007, Pages 1758-1763

  Munir, A ^a   Song, F ^a   Ince, P ^a   Walters, S J ^b   Ross, R ^a   Newell Price, J ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; FLUDROCORTISONE; HYDROCORTISONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HORMONE RELEASE; HUMAN; MALE; NELSON SYNDROME; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNIVERSITY HOSPITAL; ACTH SECRETING ADENOMA; BIOSYNTHESIS; BLOOD; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CUSHING DISEASE; DRUG EFFECT; HYPOPHYSIS; HYPOPHYSIS TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PATHOLOGY; RADIOGRAPHY;

ACTH-SECRETING PITUITARY ADENOMA; ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; FEMALE; FLUDROCORTISONE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE IMAGING; MALE; NELSON SYNDROME; PANCREATITIS; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PITUITARY NEOPLASMS; PPAR GAMMA; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34249846526     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2005     Document Type: Article

References (21)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK 2006 Cushing's syndrome. Lancet 367:1605-1617
2. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF 2002 Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 56:541-551
3. Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I, Jenkins PJ, Monson JP, Besser GM, Grossman AB 2005 Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 90:4963-4969
4. Heaney AP, Fernando M, Yong WH, Melmed S 2002 Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281-1287
5. Heaney AP, Fernando M, Melmed S 2003 PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111:1381-1388
6. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P 2004 Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151:173-178
7. Hull SS, Sheridan B, Atkinson AB 2005 Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 62:259-261
8. Suri D, Weiss RE 2005 Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 90:1340-1346
9. Assie G, Bahurel H, Bertherat J, Kujas M, Legmann P, Bertagna X 2004 The Nelson's syndrome . . . revisited. Pituitary 7:209-215
10. Kelly PA, Samandouras G, Grossman AB, Afshar F, Besser GM, Jenkins PJ 2002 Neurosurgical treatment of Nelson's syndrome. J Clin Endocrinol Metab 87:5465-5469
11. Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA, Besser GM 1995 The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 80:165-171
12. Newell-Price J, Trainer P, Besser M, Grossman A 1998 The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19:647-672
13. Nolan JJ, Jones NP, Patwardhan R, Deacon LF 2000 Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17:287-294
14. Diggle PJ, Heagerty P, Liang KY, Zeger SL 2002 Analysis of longitudinal data. 2nd ed. Oxford, UK: Oxford University Press
15. Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB 2006 The PPAR-γ activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin Endocrinol (Oxf) 64:519-522
16. Andreassen M, Kristensen LO 2005 Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy. Eur J Endocrinol 153:503-505
17. Emery MN, Leontiou C, Bonner SE, Merulli C, Nanzer AM, Musat M, Galloway M, Powell M, Nikookam K, Korbonits M, Grossman AB 2006 PPAR-γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-γ receptor. Clin Endocrinol (Oxf) 65:389-395
18. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462
19. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla GK 2001 Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108:1123-1131
20. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E 2006 Retinoic acid as a novel medical therapy for Cushing's Disease in dogs. Endocrinology 147:4438-4444
21. Boscaro M, Brew Atkinson A, Bertherat J, Petersenn S, Glusman JE, Tran LL, SOM230 Cushing's Disease Study Group, Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with Cushing's disease. Program of the 87th Annual Meeting of The Endocrine Society, San Diego, CA, 2005 (Abstract P2-531)